Skip to content
Menu

HUTCHMED Receives China National Medical Products Administration Simultaneous Approval For Two New Drug Applications For Syvik Oral Small Molecule Inhibitor Targeting Spleen Tyrosine Kinase

Benzinga Newsdesk 4 hours ago

NewsFDA

Immune Thrombocytopenia ("ITP"): For the treatment of adult patients with chronic primary ITP who have had an insufficient response to at least one prior therapy; and
Warm Antibody Autoimmune Hemolytic Anemia ("wAIHA"): For the treatment of adult patients with wAIHA who who have had an insufficient response to prior corticosteroid therapy.


The approval for ITP is supported by data from ESLIM-01 (NCT05029635), a randomized, double-blinded, placebo-controlled Phase III trial in China of SYVIK® in 188 adult patients who had received at least one prior line of standard therapy. Results from ESLIM-01 study were published in The Lancet Haematology. SYVIK® demonstrated a clinically meaningful early and sustained durable platelet response in patients with primary ITP compared to placebo, with durable response rate of 48.4% compared to zero with placebo (p<0.0001). Overall response rates were 68.3% at 0–12 weeks and 70.6% at 0–24 weeks with SYVIK®, compared to 14.5% and 16.1% with placebo (p<0.0001). SYVIK® demonstrated a tolerable safety profile and improvement in quality of life.

The approval for wAIHA is supported by data from ESLIM-02 (NCT05535933), a randomized, double-blind, placebo-controlled Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to prior glucocorticoid treatment. Results from the Phase II part of ESLIM-02 were published in The Lancet Haematology. Results from the Phase III part were presented at the European Hematology Association ("EHA") 2026 Congress. SYVIK® demonstrated a significantly higher durable response rate during weeks 5–24 compared to placebo (66% vs 15%, p<0.0001). During the 24-week double-blind treatment period, SYVIK® demonstrated superior efficacy across several key metrics; specifically, the overall response rate — defined as hemoglobin ≥100 g/L with an increase of ≥20 g/L from baseline without rescue therapy — was significantly increased (70% vs 22%, p<0.0001). SYVIK® demonstrated a favorable safety profile with no treatment-related deaths or discontinuations in the SYVIK® group.

Read at benzinga.com